Natera, Inc. $NTRA Stock Holdings Increased by Elo Mutual Pension Insurance Co

Elo Mutual Pension Insurance Co boosted its stake in shares of Natera, Inc. (NASDAQ:NTRA) by 4.5% during the second quarter, according to its most recent disclosure with the SEC. The institutional investor owned 14,522 shares of the medical research company’s stock after purchasing an additional 628 shares during the period. Elo Mutual Pension Insurance Co’s holdings in Natera were worth $2,453,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in NTRA. Vanguard Group Inc. boosted its stake in shares of Natera by 2.3% during the 2nd quarter. Vanguard Group Inc. now owns 12,676,653 shares of the medical research company’s stock valued at $2,141,594,000 after buying an additional 282,826 shares during the period. JPMorgan Chase & Co. increased its stake in shares of Natera by 44.3% in the second quarter. JPMorgan Chase & Co. now owns 10,625,785 shares of the medical research company’s stock worth $1,795,125,000 after acquiring an additional 3,263,822 shares during the last quarter. Price T Rowe Associates Inc. MD raised its holdings in shares of Natera by 56.3% during the first quarter. Price T Rowe Associates Inc. MD now owns 10,537,743 shares of the medical research company’s stock worth $1,490,144,000 after acquiring an additional 3,795,315 shares in the last quarter. Geode Capital Management LLC boosted its position in Natera by 7.0% during the second quarter. Geode Capital Management LLC now owns 2,552,725 shares of the medical research company’s stock valued at $430,640,000 after purchasing an additional 166,768 shares during the last quarter. Finally, Invesco Ltd. boosted its position in Natera by 13.7% during the first quarter. Invesco Ltd. now owns 2,035,979 shares of the medical research company’s stock valued at $287,908,000 after purchasing an additional 245,719 shares during the last quarter. Institutional investors and hedge funds own 99.90% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have recently weighed in on NTRA. Wells Fargo & Company raised their price target on Natera from $175.00 to $190.00 and gave the stock an “equal weight” rating in a research note on Friday, November 7th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Natera in a research report on Wednesday, October 8th. BTIG Research boosted their target price on shares of Natera from $210.00 to $230.00 and gave the stock a “buy” rating in a research report on Friday, November 7th. Stephens increased their price target on shares of Natera from $197.00 to $235.00 and gave the stock an “overweight” rating in a research note on Thursday, November 13th. Finally, BNP Paribas upgraded shares of Natera to a “hold” rating and set a $172.00 price target on the stock in a report on Monday, October 27th. Fifteen investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $220.88.

Natera Stock Up 0.3%

NASDAQ:NTRA opened at $237.12 on Thursday. Natera, Inc. has a 12 month low of $125.38 and a 12 month high of $241.28. The firm has a market cap of $32.72 billion, a price-to-earnings ratio of -103.55 and a beta of 1.75. The company’s 50 day moving average is $190.07 and its 200-day moving average is $169.57.

Natera (NASDAQ:NTRA) last posted its quarterly earnings data on Friday, November 7th. The medical research company reported ($0.64) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($0.25). The firm had revenue of $592.18 million for the quarter, compared to the consensus estimate of $514.55 million. Natera had a negative return on equity of 25.07% and a negative net margin of 14.61%.Natera’s quarterly revenue was up 34.7% on a year-over-year basis. During the same period in the prior year, the company posted ($0.26) earnings per share. Research analysts predict that Natera, Inc. will post -1.49 EPS for the current fiscal year.

Insider Buying and Selling

In other Natera news, CEO Steven Leonard Chapman sold 160,703 shares of the firm’s stock in a transaction that occurred on Monday, November 3rd. The stock was sold at an average price of $199.96, for a total value of $32,134,171.88. Following the sale, the chief executive officer owned 144,816 shares of the company’s stock, valued at $28,957,407.36. This trade represents a 52.60% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, insider Solomon Moshkevich sold 3,000 shares of Natera stock in a transaction that occurred on Monday, November 3rd. The stock was sold at an average price of $198.60, for a total value of $595,800.00. Following the completion of the transaction, the insider directly owned 112,061 shares in the company, valued at approximately $22,255,314.60. This represents a 2.61% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 308,366 shares of company stock valued at $63,050,068 in the last quarter. Insiders own 5.63% of the company’s stock.

Natera Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.